Department of Epidemiology of Microbial Diseases, Yale University School of Public Health, New Haven, CT, USA.
Department of Internal Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, CT, USA.
Med. 2024 Apr 12;5(4):321-334.e3. doi: 10.1016/j.medj.2024.02.005. Epub 2024 Mar 20.
Neurosyphilis is increasing in prevalence but its pathophysiology remains incompletely understood. This study assessed for CNS-specific immune responses during neurosyphilis compared to syphilis without neurosyphilis and compared these immune profiles to those observed in other neuroinflammatory diseases.
Participants with syphilis were categorized as having neurosyphilis if their cerebrospinal fluid (CSF)-venereal disease research laboratory (VDRL) test was reactive and as having syphilis without neurosyphilis if they had a non-reactive CSF-VDRL test and a white blood cell count <5/μL. Neurosyphilis and syphilis without neurosyphilis participants were matched by rapid plasma reagin titer and HIV status. CSF and plasma were assayed for markers of neuronal injury and glial and immune cell activation. Bulk RNA sequencing was performed on CSF cells, with results stratified by the presence of neurological symptoms.
CSF neopterin and five CSF chemokines had levels significantly higher in individuals with neurosyphilis compared to those with syphilis without neurosyphilis, but no markers of neuronal injury or astrocyte activation were significantly elevated. The CSF transcriptome in neurosyphilis was characterized by genes involved in microglial activation and lipid metabolism and did not differ in asymptomatic versus symptomatic neurosyphilis cases.
The CNS immune response observed in neurosyphilis was comparable to other neuroinflammatory diseases and was present in individuals with neurosyphilis regardless of neurological symptoms, yet there was minimal evidence for neuronal or astrocyte injury. These findings support the need for larger studies of the CSF inflammatory response in asymptomatic neurosyphilis.
This work was funded by the National Institutes of Health, grants K23MH118999 (S.F.F.) and R01NS082120 (C.M.M.).
神经梅毒的患病率正在上升,但它的发病机制仍不完全清楚。本研究评估了神经梅毒患者与无神经梅毒的梅毒患者的中枢神经系统特异性免疫反应,并将这些免疫特征与其他神经炎症性疾病进行了比较。
如果脑脊液(CSF)-性病研究实验室(VDRL)检测呈阳性,则将患有梅毒的患者归类为患有神经梅毒;如果 CSF-VDRL 检测呈阴性且白细胞计数<5/μL,则将其归类为患有无神经梅毒的梅毒。通过快速血浆反应素滴度和 HIV 状态对神经梅毒和无神经梅毒的患者进行匹配。检测 CSF 和血浆中神经元损伤、神经胶质细胞和免疫细胞激活的标志物。对 CSF 细胞进行批量 RNA 测序,并根据是否存在神经症状对结果进行分层。
与无神经梅毒的梅毒患者相比,神经梅毒患者的 CSF 中新蝶呤和五种 CSF 趋化因子的水平显著升高,但神经元损伤或星形胶质细胞激活的标志物并未显著升高。神经梅毒患者的 CSF 转录组以参与小胶质细胞激活和脂质代谢的基因为特征,无症状与有症状的神经梅毒病例之间没有差异。
神经梅毒患者观察到的中枢神经系统免疫反应与其他神经炎症性疾病相似,并且无论是否存在神经系统症状,都存在于神经梅毒患者中,但神经元或星形胶质细胞损伤的证据很少。这些发现支持对无症状神经梅毒患者的 CSF 炎症反应进行更大规模的研究。
这项工作得到了美国国立卫生研究院的资助,资助项目包括 K23MH118999(S.F.F.)和 R01NS082120(C.M.M.)。